We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0QNA market cap is 554.49M. The company's latest EPS is CHF 0.8708 and P/E is 51.05.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | |
| Total Revenue | 114.79M | 112.42M | 131.56M | 122.32M | 150.28M |
| Operating Income | -17.2M | -23.26M | 1.17M | 18.54M | 19.21M |
| Net Income | -22.42M | -14.72M | -6.83M | 12.15M | 10.45M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | |
| Total Assets | 221.47M | 229.79M | 247.27M | 220.85M | 173.29M |
| Total Liabilities | 314.43M | 331.84M | 305.87M | 241.56M | 183.29M |
| Total Equity | -92.96M | -102.05M | -58.61M | -20.72M | -10M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | |
| Operating | -63.84M | -54.13M | -32.02M | 7.06M | 14.25M |
| Investing | -404k | -34.96M | 3.58M | 91.65M | -1.03M |
| Financing | 1.31M | 45.07M | 16.64M | -45.25M | -57.31M |
| Market Cap | 554.49M |
| Price to Earnings Ratio | 51.05 |
| Price to Sales Ratio | 3.55 |
| Price to Cash Ratio | 8.9 |
| Price to Book Ratio | -53.34 |
| Dividend Yield | - |
| Shares Outstanding | 12M |
| Average Volume (1 week) | 4.01k |
| Average Volume (1 Month) | 4.21k |
| 52 Week Change | 0.00% |
| 52 Week High | 46.20 |
| 52 Week Low | 46.20 |
| Spread (Intraday) | 2.3 (4.86%) |
| Company Name | Basilea Pharmaceutica Ag |
| Address |
grenzacherstrasse 487 basel 4058 |
| Website | https://www.basilea.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
